Kun Peng

3.6k total citations · 2 hit papers
84 papers, 2.5k citations indexed

About

Kun Peng is a scholar working on Molecular Biology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kun Peng has authored 84 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 26 papers in Immunology and 22 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kun Peng's work include Monoclonal and Polyclonal Antibodies Research (18 papers), Biosimilars and Bioanalytical Methods (13 papers) and RNA Interference and Gene Delivery (9 papers). Kun Peng is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (18 papers), Biosimilars and Bioanalytical Methods (13 papers) and RNA Interference and Gene Delivery (9 papers). Kun Peng collaborates with scholars based in China, United States and Switzerland. Kun Peng's co-authors include Saloumeh K Fischer, Long Chen, John G. Matthews, Zhou Xiang, Barry Shane, Zhengjin Jiang, Cécile Holweg, Wendy S. Putnam, Julie Olsson and Mark D. Eisner and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Kun Peng

76 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

2016 350 citations Nicola A. Hanania, Phillip E. Korenblat et al. The Lancet Respiratory Medicine profile →
Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies

2022 153 citations Hongjian Li, Kun Peng et al. Theranostics profile →

Peers

Countries citing papers authored by Kun Peng

Since Specialization

Citations

This map shows the geographic impact of Kun Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun Peng more than expected).

Fields of papers citing papers by Kun Peng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kun Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun Peng. The network helps show where Kun Peng may publish in the future.

Co-authorship network of co-authors of Kun Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Kun Peng. A scholar is included among the top collaborators of Kun Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kun Peng. Kun Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Research trends of protein palmitoylation in cancer from 2004 to 2024: a bibliometric and visualization analysis 2025 ·Frontiers in Oncology ·Yufeng Peng, Kun Peng, (unknown), (unknown), (unknown)	0
2	Reformation of a Clinical Anti-Drug Antibody Assay to Enable the Immunogenicity Assessment of a Bispecific Antibody Biotherapeutic 2024 ·The AAPS Journal ·Wenyu Liu, Jie Yang, Weili Yan, Kun Peng	0
3	Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies 2024 ·mAbs ·Wen‐Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui Phung, (unknown), Kun Peng, Dan Qin, (unknown), Christoph Spiess, Jochen Brumm, Manda Wong, Zhengmao Ye, Patrick Wu, Sivan Cohen, Paul J. Carter	7
4	Biomimetic fabrication bioprinting strategies based on decellularized extracellular matrix for musculoskeletal tissue regeneration: Current status and future perspectives 2024 ·Materials & Design ·(unknown), Fei Xing, Peiyun Yu, (unknown), Shanshan Ma, (unknown), Zhou Xiang, Kun Peng, (unknown), (unknown)	10
5	A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma 2024 ·Clinical Pharmacology & Therapeutics ·Chi‐Chung Li, Brendan C. Bender, Justin Wilkins, (unknown), David C. Turner, Bei Wang, Rong Deng, Shweta Vadhavkar, Zao Li, Antonia Kwan, Huang Huang, Kun Peng, Elicia Penuel, Ling‐Yuh Huw, Pascal Chanu, (unknown), (unknown), (unknown), (unknown)	3
6	Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies breakdown → 2022 ·Theranostics ·Hongjian Li, Kun Peng, Kai Yang, Wenbo Ma, Shaolong Qi, (unknown), Jia He, Xin Lin, Guocan Yu	153
7	An integrated approach for characterizing immunogenic responses toward a bispecific antibody 2021 ·mAbs ·Sivan Cohen, Shan Chung, Christoph Spiess, Victor F. Lundin, Eric Stefanich, Steven T. Laing, Vanessa Clark, Jochen Brumm, (unknown), Catherine Huang, (unknown), (unknown), Rajbharan Yadav, (unknown), Kun Peng	16
8	Anserine and glucosamine supplementation attenuates the levels of inflammatory markers in rats with rheumatoid arthritis 2020 ·AMB Express ·(unknown), (unknown), (unknown), (unknown), Kun Peng	14
9	Inhibition of miR-22 promotes differentiation of osteoblasts and improves bone formation via the YWHAZ pathway in experimental mice 2019 ·Archives of Medical Science ·(unknown), (unknown), Fan Xiao, Biao Zhao, Yu Wang, Kai Wu, Kun Peng	7
10	Biomimetic small peptide functionalized affinity monoliths for monoclonal antibody purification 2018 ·Analytica Chimica Acta ·Xiangyu Wang, (unknown), Hai Han, Kun Peng, (unknown), Jacques Crommen, Qiqin Wang, Zhengjin Jiang	26
11	Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study) 2017 ·The American Journal of Cardiology ·Amos Baruch, Sofia Mosesova, John D. Davis, Nageshwar Budha, (unknown), Robert S. Kahn, Kun Peng, Kyra J. Cowan, (unknown), Thomas Gelzleichter, (unknown), John C. Davis, Whittemore G. Tingley	44
12	Risk factors for endophthalmitis requiring evisceration or enucleation 2016 ·Scientific Reports ·(unknown), Danny Siu‐Chun Ng, (unknown), Kun Peng, (unknown), (unknown), Weiqi Chen, Haoyu Chen	42
13	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials breakdown → 2016 ·The Lancet Respiratory Medicine ·Nicola A. Hanania, Phillip E. Korenblat, Kenneth R. Chapman, Eric D. Bateman, Petr Kopecký, Pierluigi Paggiaro, Akihito Yokoyama, Julie Olsson, Sarah Gray, Cécile Holweg, Mark D. Eisner, Charles Asare, Saloumeh K Fischer, Kun Peng, Wendy S. Putnam, John G. Matthews	350
14	Pre-existing Antibody: Biotherapeutic Modality-Based Review 2016 ·The AAPS Journal ·Boris Gorovits, Adrienne Clements‐Egan, Mary Birchler, Meina Liang, Heather Myler, Kun Peng, Shobha Purushothama, Manoj Rajadhyaksha, Laura I. Salazar‐Fontana, Crystal Sung, Xue Li	57
15	Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 2015 ·The AAPS Journal ·Nageshwar Budha, Maya K. Leabman, Jin Y. Jin, Daisuke Wada, Amos Baruch, Kun Peng, Whittemore G. Tingley, John D. Davis	15
16	Mechanistic Pharmacokinetic-Pharmacodynamic Modeling of BACE1 Inhibition in Monkeys: Development of a Predictive Model for Amyloid Precursor Protein Processing 2013 ·Drug Metabolism and Disposition ·Xingrong Liu, Harvey Wong, Kimberly Scearce‐Levie, Ryan J. Watts, Melis Coraggio, Young G. Shin, Kun Peng, Kristin R. Wildsmith, Jasvinder K. Atwal, (unknown), Stephen Schauer, Kelly Regal, Kevin W. Hunt, Allen A. Thomas, Michael Siu, Joseph P. Lyssikatos, Gauri Deshmukh, Cornelis E. C. A. Hop	17
17	A Homogeneous Enzyme Fragment Complementation-Based β-Arrestin Translocation Assay for High-Throughput Screening of G-Protein-Coupled Receptors 2008 ·SLAS DISCOVERY ·Xiaoning Zhao, (unknown), Keith R. Olson, Kun Peng, Tom S. Wehrman, Adam Park, (unknown), (unknown), Stephen W. Young, Shou-Hua Xiao	56
18	A Homogeneous Cell-Based Assay to Measure Nuclear Translocation Using β-Galactosidase Enzyme Fragment Complementation 2006 ·Assay and Drug Development Technologies ·(unknown), Kun Peng, (unknown), (unknown), (unknown), Keith R. Olson, Richard M. Eglen	17
19	Polymorphisms in Cytoplasmic Serine Hydroxymethyltransferase and Methylenetetrahydrofolate Reductase Affect the Risk of Cardiovascular Disease in Men 2005 ·Journal of Nutrition ·Unhee Lim, Kun Peng, Barry Shane, Patrick J. Stover, Augusto A. Litonjua, Scott T. Weiss, J. Michael Gaziano, Robert L. Strawderman, Farbod Raiszadeh, Jacob Selhub, Katherine L. Tucker, Patricia A. Cassano	39
20	Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations 1999 ·Genetic Epidemiology ·Dawn L. Harmon, Denis C. Shields, Jayne V. Woodside, Dorothy McMaster, J. W. G. Yarnell, Ian Young, Kun Peng, Barry Shane, Alun E. Evans, Alexander S. Whitehead	210

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact